Accelerated Clinical Evaluation of a Monovalent Vectored Ebola vaccine (360G-Wellcome-106325_Z_14_Z)
Conversations between the principal investigator, The Wellcome Trust and various other parties have led to this application being submitted for fast track assessment. The goal is to demonstrate the safety and immunogenicity in UK and West African adults of a vaccine for the Zaire strain of Ebola virus that has shown significant promise in pre-clinical studies conducted at the NIH in collaboration with Okairos, now GSK. Demonstration of the safety and immunogenicity of this vaccine by November 2014 in about 140 subjects would provide WHO with the option of providing this vaccine to affected countries, particularly for use in health care workers, for whom no other intervention is currently available.
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
| Amount Awarded | 910000 |
| Applicant Surname | Hill |
| Approval Committee | Board of Governors |
| Award Date | 2014-08-29T00:00:00+00:00 |
| Financial Year | 2013/14 |
| Grant Programme: Title | Ebola Research Support Initiative |
| Internal ID | 106325/Z/14/Z |
| Lead Applicant | Prof Adrian Hill |
| Other Applicant(s) | Prof Myron Levine, Prof Umberto D'Alessandro |
| Partnership Name | Ebola Research Support Initiative |
| Partnership Value | 2820000 |
| Planned Dates: End Date | 2016-12-31T00:00:00+00:00 |
| Planned Dates: Start Date | 2014-09-01T00:00:00+00:00 |
| Recipient Org: Country | United Kingdom |
| Region | South East |